Ignite Creation Date:
2024-05-05 @ 11:43 PM
Last Modification Date:
2024-10-26 @ 10:38 AM
Study NCT ID:
NCT01392729
Status:
COMPLETED
Last Update Posted:
2016-11-02
First Post:
2011-07-11
Brief Title:
An Observational Study of Avastin Bevacizumab and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer VERA
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open Label Prospective Observational Local Non-interventional Study of BeVacizumab Avastin and IntErpherone IFN Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer VERA Study
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective observational study will evaluate the efficacy and safety of Avastin bevacizumab in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer Data will be collected from each patient for up to 4 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None